Full Press Release Details
Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB September
Forward-Looking Statements This communication contains forward-looking statements
(including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and
other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company's management, as well as
assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as
"may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," "forecast," "guidance", "outlook" and other similar expressions among others. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various
factors, including, without limitation: the Company's ability to protect its intellectual property rights; the Company's anticipated capital requirements, including the Company's anticipated cash runway and the Company's current expectations
regarding its plans for future equity financings; the Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional
capital may restrict the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates; the Company's limited operating history in the Company's current line of business, which makes it
difficult to evaluate the Company's prospects, the Company's business plan or the likelihood of the Company's successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials
for PDS0101 and other Versamune and Infectimune based product candidates; the future success of such trials; the successful implementation of the Company's research and development programs and collaborations, including any collaboration
studies concerning PDS0101 and other Versamune and Infectimune based product candidates and the Company's interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the
future success of the Company's product candidates; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of
initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company's currently projected expenses), futility analyses,
presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the
Company's ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any
collaboration studies; to aid in the development of the Versamune platform; and other factors, including legislative, regulatory, political and economic developments not within the Company's control. The foregoing review of important factors
that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's
annual, quarterly and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Versamune and Infectimune are registered trademarks of PDS Biotechnology
Corporation KEYTRUDA is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or
metastatic, HPV16-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation PDS0101 addresses large and growing market with significant unmet need Transformational data generated with PDS0101 and PDS0301 in multiple Phase 2
clinical studies Financial: Cash as of June 30, 2023 - $60.6M- Adequate cash runway for the next 12 months with initiation of a registrational trial in 2023 Executive Summary: Positioned for Market Leadership Company Overview T cell
activating platforms and antibody conjugated immuno-cytokine platform to develop safer, more effective and longer lasting cancer immunotherapies 1 2 3 4
Experienced Management Team Historical success in development and
commercialization of leading pharmaceutical products Frank Bedu-Addo, PhD Chief Executive Officer Senior executive experience with management of strategy and execution at both large pharma and biotechs Notable drug development: Abelcet
(Liposome Company/ Elan) PEG-Intron (Schering-Plough/ Merck) Matthew Hill Chief Financial Officer 20 years of financial and operational leadership roles for life sciences companies Former Chief Financial Officer of several publicly traded
companies Lauren V. Wood, MD Chief Medical Officer 30 years of translational clinical research experience Former Vaccine Branch Clinical Director at National Cancer Institute Center for Cancer Research Gregory Conn, PhD Chief Scientific
Officer Co-founder 35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing
PDS Biotech Versamune Overview Designed to address limitations of current
immunotherapy PLATFORM: Induces powerful, long-lasting anti-tumor response by promoting uptake of tumor-specific proteins by the immune system and activates a specific signaling pathway that promotes the production of active
tumor-infiltrating multifunctional CD8 killer and CD4 helper T cells Versamune PDS0101 PDS0102 PDS0103 PDS0104 Product Candidates
Versamune Induces the Right Type, Potency and Quantity of Multifunctional Killer
and Helper T Cells Comprised of positively charged lipid (R-DOTAP) co-administered with proprietary tumor-specific proteins, delivered via subcutaneous injection Delivers antigen to CD4 and CD8 T cells. Activates the Type I Interferon
pathway, leading to potent, multifunctional, antigen specific T cell responses Human clinical trials confirm induction and accumulation of multifunctional T cells in the tumor, which correlated with clinical response and elimination of
circulating tumor DNA and clinical response (SITC 2022) Recruits T cells to lymph nodes Trains T cells to target tumors Arms T cells to kill tumor cells 1 2 3 Injection Site Lymph Node Tumor Site References: Gandhapudi SK, et al.
2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536. Smalley Rumfield C et al. 2020. Immunomodulation to
enhance the efficacy of an HPV therapeutic vaccine. J. for ImmunoTherapy of Cancer 8:e000612.
IMMUNOCERV: PDS0101 Appears to Induce Clinically Beneficial Killer (CD8) T
Cells PDS0101 activates the immune system to generate active killer T cells (CD8 T) cells that induce a critical mediator of the T cell's tumor-killing function called granzyme-B Multifunctional killer T cells target, infiltrate and eliminate
the cervical cancer tumors HPV16 tumor DNA in the blood circulation declines by day 170 (T5) Quantity of tumor cell DNA circulating in the blood Killer T cells that infiltrated the tumors Representative Subject IMMUNOCERV
(PDS0101+Chemoradiation) Trial1: Predominantly stage III and IV cervical cancer Locally advanced cancer with tumors > 5cm (high-risk patients) 100% (9/9) clinical response rate with 60 days No evidence of cancer in 89% (8/9) by Day
170 Induction of activated CD8 T cells correlates with elimination of circulating tumor DNA1 1Yoshida-Court et al,, IMMUNOCERV, an ongoing Phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation
for treatment of locally advanced cervical cancers (NCT04580771); SITC 2022
HPV16-Positive Head and Neck Squamous Cell Cancer (HNSCC) Disease Overview and
Est. HPV16Locally Advanced,Unresectable andMetastatic HPV16-positive HNSCC
Presents a Significant Market Opportunity Largely Attributed to the High Rate of Oral HPV Infections in Men Data sources: 1 PD-L1 negative and PD-L1 positive populations (> 9000 incidence PD-L1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002133/ ~18,300 ~34,000 ~38,100 ~54,400 Est. U.S. HPV Positive Oral and Pharyngeal Cancer Est. U.S. Oral and Pharyngeal Cancer Est. HPV16 Genotype $2-3B Market Opportunity in US1 HPV
cancer incidences continue to increase despite preventive HPV vaccine HPV vaccination is not expected to impact the rate of HPV-positive cancer incidence for the near-term Existing immunotherapies cost $150,000+ annually per patient1 No
available HPV specific therapy Initial commercial opportunity for PDS0101
Targeted treatment option to address the growing population of HPV16-positive
HNSCC and improve outcomes Novel MOA that is clinically effective in a broader patient population and provides more durable responses. Safer and more effective treatments that may be used with or in place of current standard of care
Better tolerability and less toxic alternatives to chemotherapy Despite the Availability of Treatments, Significant Unmet Needs Remain in Recurrent or Metastatic HNSCC KEYTRUDA KEYTRUDA Plus Chemo Chemotherapy + EGFR
Inhibitor Objective Response Rate (ORR) 19% 36% 35% Progression Free Survival (PFS) 3.2 mos 5.0 mos 5.0 mos 12-Month Survival Rate 50% 55% 44% Median Overall Survival (OS) 12.3 mos 13.6 mos 10.3 mos Key
Toxicities Anemia Fatigue Weight loss Hypokalemia Additional to KEYTRUDA : Neutropenia Mucosal inflammation Thrombocytopenia Stomatitis Neutropenia Anemia Thrombocytopenia Nausea/vomiting Hypokalemia Rash Fatigue Mucosal
inflammation Treatment Related Grade 3+ Toxicities 17% 72% 69% Oncologist2 - Stated Unmet Medical Needs in HNSCC Standard of Care for Recurrent or Metastatic HNSCC - Published Results*1 1KEYNOTE-048 Study Burtness B et al, Lancet
2019 2Primary Market Research 2022 * No control or comparative studies have been conducted between immune checkpoint inhibitors and PDS0101
PDS0101 for HPV16-Positive HNSCC
VERSATILE-002 Phase 2 Clinical Trial Objective: To assess the combination of
PDS0101 and KEYTRUDA in ICI na ve subjects with recurrent or metastatic HPV-positive HNSCC KEYTRUDA (pembrolizumab) FDA Approved Standard of Care Partner Study Design Open-label, non-randomized, adaptive design study N=54 Enrollment
complete Key Entry Criteria for ICI Na ve Subjects Recurrent or metastatic HNSCC 18 years of age HPV16-Positive tumor Combined positive score (CPS) 1 Pembrolizumab 200mg IV Q3W up to 35 Cycles (2 years) PDS0101 1 mL subcutaneous
injection at Cycles 1, 2, 3, 4 and 12 Study Treatment Primary: Best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1 Key Secondary: Progression Free Survival (PFS) per RECIST
1.1 Overall Survival (OS) Safety and tolerability Achievement of Statistical Threshold for efficacy Endpoints Fast TrackDesignation
To Date 70.6% of Patients have Achieved Disease Stabilization or Tumor
Shrinkage Confirmed best overall response was determined based on confirmed CR or confirmed PR per RECIST 1.1 per investigator assessment. One subject (NE) died prior to target lesion measurement and is included in the mITT population
denominator. Four subjects experienced unconfirmed tumor shrinkage and subsequently experienced progressive disease. 30%Shrinkage 14/34 (41.2%) Confirmed and Unconfirmed Objective Response 9/34 (26.5%) Confirmed Partial and Complete
Response 15/34 (44.1%) Stable Disease 9/34 (26.5%) Progressive Disease 1/34 (2.9%) Not Evaluable (not included in Waterfall plot) 23/34 (67.6%) Tumor Reduction Statistically significant improvement in the Response Rate of PDS0101+
KEYTRUDA vs. KEYTRUDA monotherapy confirmed
The Addition of PDS0101 to KEYTRUDA Does not Appear to Compound Toxicity Only 4
subjects (8%) had Grade 3 PDS0101-KEYTRUDA TRAEs: fatigue, injection site reaction, blood alkaline phosphatase increased, hyperglycemia, colitis, and rash No subjects had Grade 4 or 5 TRAEs No subject came off study due to
toxicity PDS0101+KEYTRUDA Treatment Related Adverse Events (TRAE) >5% (ITT Population) Safety data in approximately 120 patients to date across multiple Phase 1 and 2 Studies Safety data, anti-tumor responses and patient survival suggest
that the Versamune based therapies such as PDS0101 could be ideal candidates for combination oncology treatments
Data Suggests Prolonged Responses (Durability) and Patient Survival PDS0101 +
KEYTRUDA Data - Median PFS and 12 Month OS *median OS for PDS0101 + KEYTRUDA not yet reached KEYNOTE-048: Burtness B et al. Lancet 2019;394:1915-28, Published results for reference only 15 10.4 months 3.2 months 5.0
months 55% 87.1% 50% Median Progression Free Survival (Months) 12-Month OS Rate (%)* No control or comparative studies have been conducted between immune checkpoint inhibitors and PDS0101
Several Patients Approaching Two Years of Survival Overall response: CR=Complete
Response; PR=Partial Response; SD=Stable Disease; PD=Progressive Disease; NE=Not Evaluable. Overall response was based on investigator assessment per RECIST v1.1. Survival status: A=Alive; D=Deceased. Alive subjects were based on the last
contact date. Complete Response Partial Response Stable Disease Progressive Disease Demonstrated objective response rate of 41% (confirmed and unconfirmed) No control or comparative studies have been conducted between immune checkpoint
inhibitors and PDS0101
VERSATILE-003 Timeline to Registrational Trial Initiation Worldwide Randomized,
Controlled Clinical Study to Be Initiated Q4 2023 with an Overall Estimated 90-100 Sites PDS0101 + KEYTRUDA in Recurrent or Metastatic HPV16-Positive HNSCC 2Q 2022 3Q 2022 1Q 2023 2Q 2023 3Q 2023 4Q 2023 FDA Fast Track designation for
PDS0101 + KEYTRUDA Successful EOP2 meeting with FDA Initiated PDS0101 tech-transfer, scale up at selected Phase 3 clinical/commercial manufacture Completed Phase 3 clinical manufacturing of PDS0101 Obtained visibility to potential OS and
PFS information for VERSATILE-002 trial needed to finalize VERSATILE-003 trial design Completed CMC-related activities for PDS0101 Obtained feedback from EU regulatory agencies on protocol Submitted amended IND with FDA for registrational
trial Initiate site activation and related clinical, operational activities (4- to 6-month process) InitiateVERSATILE-003 Phase 3 Trial VERSATILE-002 Phase 2 Trial Progressing
Versamune Based Oncology Pipeline Partnerships with World Class Institutions in
Immuno-Oncology Reference: Data on file. PDS Biotech Funded Candidate/ Study Indication Combination PC P1 P2 P3 R Partner(s) Clinical (Lead) PDS0101 (HPV)/ VERSATILE-002 Recurrent or metastatic HPV16-positive head and neck
cancer Arm 1: ICI na ve Arm 2: ICI refractory KEYTRUDA (standard of care) IIT Studies PDS0101 (HPV)/ IMMUNOCERV 1st-line treatment of locally advanced (IB3-IVA) cervical cancer Chemo-radiation (standard of care) PDS0101 (HPV)/ Mayo
Clinic Pre-metastatic HPV-positive oropharyngeal cancer (OPSCC) Arm 1: PDS0101 monotherapy Arm 2: PDS0101 + KEYTRUDA KEYTRUDA (standard of care) Preclinical Candidates PDS0102(TARP) TARP-positive AML, prostate and breast
cancers TBD PDS0103 (MUC1) MUC1-positive breast, colon, lung, ovarian and other cancers TBD PDS0104(TRP2) Melanoma TBD Partner Co-Funded Fast Track Designation
Antibody-Conjugated IL-12 (PDS0301)
PDS Biotech Antibody-Conjugated IL-12 (PDS0301) Overview Antibody-Conjugated
IL-12 Opportunities PDS0301 is a novel investigational tumor-targeting IL-12 that enhances the proliferation, potency and longevity of T cells in the tumor microenvironment Monotherapy Combinations: Versamune Based
Immunotherapies Chemotherapy Radiation HDAC Inhibitors* *Histone Deacetylase Inhibitor
NCI-led Triple Combination: PDS0301 + PDS0101 + ICI Advanced HPV16-Positive Anal,
Cervical, Head and Neck, Penile, Vaginal, Vulvar Cancer Patients Who Are ICI Refractory 172% grade 3 and higher adverse events reported in KEYNOTE-048 Burtness 2019 https://doi.org/10.1016/S0140-6736(19)32591-7 Goswami 2022
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0695 Partner FDA Approved Standard of Care None Immunology/Immune Correlates SITC, November 2022: Greater than two-fold increase in HPV16-specific T cells in the blood of 11/14 (79% ) of the